KospicyKorean filings in English
Filings / INCON Co., Ltd.

Beneficial Ownership Report (5%) — Standard Form

INCON Co., Ltd. · 주식등의대량보유상황보고서(일반)

SC 13D/GKOSDAQ · 083640 Filed 2026-11-13Korean original on DART

English form view 68% translated

Translated from a fixed dictionaryLeft in Korean (free text, names)Numbers and dates are copied unchanged

Report on large shareholdings (general)

6.1

주식회사 인콘

0000

20261106

Report on Large Holdings of Shares, etc.

(General form: reports under Article 147 of the Financial Investment Services and Capital Markets Act with the purpose of influencing management control)
To: Financial Services CommissionReporting obligation date:2026-11-06
To: Korea ExchangeReport reference date:2026-11-13
Reporting person:(주)미래아이앤지
Summary
Issuer name주식회사 인콘Relationship to IssuerLargest Shareholder
Report TypeChange
Number of Shares Held and Holding RatioNumber of Shares HeldHolding Ratio
Previous Report2,546,35255.46
Current Report4,028,56566.33
Shares under key agreements: number and ratioNumber of shares, etc.Ratio
Previous Report--
Current Report1,482,21324.40
Number of voting rights and holding ratioNumber of Voting RightsHolding Ratio
Previous Report--
Current Report--
Voting rights under key agreements: number and ratioNumber of Voting RightsRatio
Previous Report--
Current Report--
Reason for Report발행회사의 전환사채매도청구권 행사자 지정
※ The reporting person confirms that holdings of shares, etc. by the reporting person and specially related parties as of the reference date are accurately stated per applicable laws and filing instructions, with no material misstatement or omission.

Part 1 Report Overview

1. Issuer information

Company Name주식회사 인콘Company code083640
Entity typeKOSDAQ-Listed CompanyTotal Issued Voting Shares (shares)4,591,668

- 상기 의결권있는 발행주식 총수는 신규 상장예정인 7,414,273주 포함하였습니다.

2. Major shareholder information

a. Reporting person

(1) Reporting person overview

Report TypeChangeJoint signatories
Reporting person typeDomestic corporationNationalityRepublic of Korea
Basis for Reporter Classification (only if reported as a statutory partnership or other entity)-
Name (Entity Name)Korean주식회사 미래아이앤지Chinese characters (English)MiraeING.Co.LTD
Address (Head Office) [Town/District Level Only]서울특별시 강남구 삼성동Date of Birth or Business Registration No., etc.114-81-10728
Occupation (business)금융솔루션Relationship to IssuerLargest Shareholder
Business contact and person in chargeAffiliated company주식회사 미래아이앤지DepartmentCorporate Planning Team
PositionManagerPhone Number02-347**
Name장승진Fax number02-581*
Email address**[email protected]

(2) 보고자에 대한 구체적인 사항(법인, 기타단체, 법령상조합, 민법상 조합의 경우 기재)주식회사 미래아이앤지

Legal formCo., Ltd.
Total Assets (or Total Assets Under Management)70,534Total Liabilities21,892
Total Equity48,643Paid-in Capital14,439
Representative (representative or managing partner)박우람
Decision-Making Body (Decision Maker)이사회, 주주총회
Largest Shareholder (Largest Investor)(유한)스텔라이노베이션투자목적회사Largest Shareholder Ownership (%) (Largest Investor Contribution Ratio)31.10

【보고자의 최대주주가 법인, 기타단체, 법령상조합, 민법상 조합의 경우】

Legal form자본시장법에 따른 기관전용 사모집합투자기구
Total Assets (or Total Assets Under Management)125,100Total Liabilities-
Total Equity125,100Paid-in Capital125,100
Representative (representative or managing partner)김창근
Decision-Making Body (Decision Maker)업무집행사원 : 주식회사 스텔라프라이빗에쿼티
Largest Shareholder (Largest Investor)스텔라이노베이션사모투자 합자회사Largest Shareholder Ownership (%) (Largest Investor Contribution Ratio)100

b. Specially related parties

(1) Specially related party overview

No.NameCategorySpecific Relationship to ReporterDate of Birth or Business Registration No., etc.NationalityAddress (Location)Occupation (Business)Relationship to Issuer
1주식회사 케이바이오랩스Domestic corporationAffiliate220-81-45629Republic of Korea서울특별시 강동구 올림픽로바이오 유통사업Major Shareholder
* Address to town/district level only

(2) Details of specially related parties (for corporations, other entities, statutory or civil-law partnerships)

Legal formCo., Ltd.
Total Assets (or Total Assets Under Management)118,842Total Liabilities16,561
Total Equity102,281Paid-in Capital11,571
Representative (representative or managing partner)조안협, 이영철
Decision-Making Body (Decision Maker)이사회, 주주총회
Largest Shareholder (Largest Investor)주식회사미래아이앤지Largest Shareholder Ownership (%) (Largest Investor Contribution Ratio)40.99

- 특별관계자의 최대주주는 이 보고서의 보고자임으로, 상기 보고자에 대한 구체적인 사항 참고

c. Collective investment manager

No.NameBusiness Registration No., etc.Target collective investment vehicleNationalityAddress (Location)Remarks
-------

- N/A

3. Shares, etc. held and holding ratio

Report reference dateReporting personShares, etc.Share CertificatesTotal Issued Voting Shares (shares)
Name of HolderNumber of Specially Related PersonsNumber of Shares, etc. (shares)Ratio (%)Number of Shares (shares)Ratio (%)
Previous Report2026-09-04주식회사 미래아이앤지22,546,35255.462,546,35255.464,591,668
This Report2026-11-13주식회사 미래아이앤지24,028,56566.332,546,35255.464,591,668
Change1,482,21310.87000

4. Purpose of holding

Impact on management control

| 보고자 본인은 자본시장과 금융투자업에 관한 법률 시행령 제154조 제1항 각 호에 대한 사항에 대하여 회사의 최대주주로서 회사에 영향력을 행사할 예정입니다. 현재 아래 1~10 각 호의 사항에 대한 세부 계획은 없지만, 회사의 최대주주로서 회사의 업무집행과 관련한 각 호의 사항이 발생할 경우에는 회사의 경영목적에 부합하도록 관련 행위들을 결정할 예정입니다. |
1.이사 및 감사의 선임ㆍ해임 또는 직무의 정지
2.이사회 등 회사의 기관과 관련된 정관의 변경
3. 회사의 자본금의 변경
4. 회사의 배당의 결정
5. 회사의 합병, 분할 및 분할합병
6. 주식의 포괄적 교환 및 이전
7. 영업전부의 양수ㆍ양도 또는 금융위원회가 정하여 고시하는 중요한 일부의양수ㆍ양도
8. 자산의 전부의 처분 또는 금융위원회가 정하여 고시하는 중요한 일부의 처분
9. 영업전부의 임대 또는 경영위임, 타인과 영업의 손익전부를 같이 하는 계약,그 밖에 이에 준하는 계약의 체결ㆍ변경 또는 해약
10. 회사의해산 |
|---|

5. Reason for change

Method of change발행회사의 전환사채매도청구권 행사자 지정
Reason for change발행회사에서 전환사채 매도청구권(Call Option)을 최대주주 및 관계회사에게 행사 할 수 있도록 지정하여 잠재주식 1,482,213주 취득
Reason for Change-

Part 2 Details of Large Holdings

1. Holdings by reporting person and specially related persons

A. Holdings by type of shares, etc.

RelationshipNameDate of Birth or Business Registration No., etc.Details of Shares Held
Share certificatesInstruments representing preemptive rightsConvertible bondsBonds with warrantsExchangeable bondsDepositary receiptsOtherTotal
Voting SharesShares Redeemable into Voting SharesShares Convertible into Voting SharesNumber of sharesRatio (%)
Reporting person(주)미래아이앤지114-81-107281,482,854-------889,3282,372,18239.06
Specially Related Party(주)케이바이오랩스220-81-456291,063,498-------592,8851,656,38327.27
-------------
Aa1a2BCDEFG
H

* 상기 '기타' 항목은 2026-11-06 발행된 제13회차

Total Issued Voting Shares (I)Number of Potential Shares Held (a1+a2+B+C+D+E+F+G=H)Holding Ratio (%)
Holding Ratio of Shares, etc. [A+H / I+H-(E+F+G)※] × 100Share Holding Ratio (A / I) × 100
4,591,6681,482,21366.3355.46

※ Holding ratio calculated excluding from the denominator only exchangeable bonds exchangeable into shares, depositary receipts and derivative-linked securities with shares as underlying, and stock options settled in treasury shares

B. Holdings by form of holding

RelationshipName (Entity Name)Date of Birth or Business Registration No., etc.Type of holding equivalent to ownership (Article 142, Enforcement Decree of the Financial Investment Services and Capital Markets Act)Total
No. 1No. 2No. 3No. 4No. 5No. 6No. 7Number of sharesRatio
Reporting person(주)미래아이앤지114-81-107281,482,854---889,328--2,372,18239.06
Specially Related Party(주)케이바이오랩스220-81-456291,063,498---592,885--1,656,38327.27
-----------
※ Holdings equivalent to ownership (Article 142, Enforcement Decree of the Financial Investment Services and Capital Markets Act) - Item 1: owning shares, etc. for one's own account, in whatever name - Item 2: holding a right to claim delivery of shares, etc. under law, a sale, or other contract - Item 3: holding voting rights (including the right to direct voting) over the shares, etc. under law, a money trust, security, or other contract - Item 4: holding the authority to acquire or dispose of the shares, etc. under law, a money trust, security, discretionary investment, or other contract - Item 5: acquiring, through a unilateral reservation for sale of shares, etc., the right to complete the sale, and holding buyer status by exercising that right - Item 6: holding contractual rights under Article 5(1)(2) of the Act with shares, etc. as underlying assets, and holding buyer status by exercising those rights - Item 7: being granted stock options and holding buyer status by exercising them

2. Contracts on shares held

A. Contract status

Execution or amendment of key agreements (trust, collateral, lending, discretionary, OTC trading, joint holding, etc.)
Yes

*Voting rights on unreported holdings may be restricted if execution/amendment of material contracts is not reported

B. Contract details

No.Name (Entity Name)Relationship to ReporterDate of Birth or Business Registration No., etc.Type of shares, etc.Number of shares, etc.CounterpartyContract typeContract date (amendment date)Contract periodRatioRemarks
1(주)미래아이앤지Self114-81-10728Other889,3281. 제이케이(JK)신기술투자조합 제21호2. 주식회사 제브라자산운용 (집합투자업자 지위에서)(ZEBRA 코스닥벤처 일반 사모투자신탁 제2호)매도청구권 지정 및 행사 협약2026-11-062026.11.06 ~2027.10.0614.64인콘 제13회CB
2(주)케이바이오랩스Related party220-81-45629Other592,8851. 제이케이(JK)신기술투자조합 제21호2. 주식회사 제브라자산운용 (집합투자업자 지위에서)(ZEBRA 코스닥벤처 일반 사모투자신탁 제2호)매도청구권 지정 및 행사 협약2026-11-062026.11.06 ~2027.10.069.76인콘 제13회CB
Total (number of shares, etc.)1,482,213Total (ratio)24.40-

- 상기 계약기간은 매도청구권 권리행사기간임. - 상기 비율은 의결권있는발행주식 총수의 매도청구권 지정분(잠재주식)을 합산하여 산출하였습니다.

C. Additional details if the main contract is a security agreement

No.Number of shares, etc.Loan amountDebtorInterest rateCollateral maintenance ratioOther
-------

3. Holdings by proprietary and customer account (financial institutions only)

NameRelationship to ReporterBy accountTotal
Own Account (shares)Ratio (%)Customer account (shares)Ratio (%)Total (shares)Ratio (%)
--------
Total------

Part 3 Material Changes Since Last Report Date

1. Summary of changes

a. Changes in shares, etc.

RelationshipNameDate of Birth or Business Registration No., etc.Details of Changes in Shares, etc.
Share certificatesInstruments representing preemptive rightsConvertible bondsBonds with warrantsExchangeable bondsDepositary receiptsOtherTotal
Voting SharesShares Redeemable into Voting SharesShares Convertible into Voting SharesNumber of sharesRatio (%)
Reporting person(주)미래아이앤지114-81-10728--------889,328889,32814.64
Specially Related Party(주)케이바이오랩스220-81-45629--------592,885592,8859.76
-------------

2. Change details

a. Detailed changes in shares, etc.

(Unit: shares, KRW)
Name (Entity Name)Date of Birth or Business Registration No., etc.Change Date*Acquisition/disposal methodType of shares, etc.Change detailsAcquisition/disposal unit price**Remarks
Before ChangeChangeAfter Change
(주)미래아이앤지114-81-107282026-11-06기타(+)Other-889,328889,328-( - )전환가액 5,060
(주)케이바이오랩스220-81-456292026-11-06기타(+)Other-592,885592,885-( - )전환가액 5,060

* For trades on the securities market, the contract date

** For securities other than shares, the exercise (conversion/exchange) price of the securities or the unit price of shares acquired/disposed of through exercise of rights; amounts in ( ) are the unit price of the securities

3. Source of acquisition funds

(1) Overview of acquisition funds

(Unit: KRW)
NameDate of birth or business registration no., etc.Own funds (H)Borrowings (I)Other (J)Total (H+I+J)
(주)미래아이앤지114-81-10728--315,000,000315,000,000
(주)케이바이오랩스220-81-45629--210,000,000210,000,000

(2) Origin and source of acquisition funds

ㅇ 기타의 경우

NameDate of birth or business registration no., etc.Source and Formation of Acquisition Funds
(주)미래아이앤지114-81-10728보유자금
(주)케이바이오랩스220-81-45629보유자금